On 22 November 2026, BAMA TEA (06980.HK) said its military procurement suspension is a sector-specific adjustment with no impact on quality or daily operations.
On 20 November 2026, GOLDSTONE CAP (01160.HK) dropped its review of the Listing Committee ruling; trading halted on 20 November and suspends from 23 November.
On 20 November 2026, CHINA JINMAO (00817.HK) put its 100% stake in the owner of JW Marriott Shenzhen on the Beijing equity exchange at RMB 1.56 billion.
On November 20, 2026, XINTE ENERGY (01799.HK) said its 49%-held associate Zhundong TBEA Energy plans to file an interbank REIT on the Shanghai Stock Exchange backed by its 2×660MW Beiyi coal-fired power plant, with XINTE to sell part or all of its stake to the manager; scale is undetermined.
On 20 November 2026, CHINARES PHARMA (03320.HK) said the tender for CR Pharmaceutical Commercial's potential share issue launched via the China Beijing Equity Exchange, seeking up to RMB5.5 billion from no more than 15 investors, with Beijing Pharmaceutical able to join with up to RMB2 billion.
On 20 November 2026, Touyun Biotech (01332.HK) said Luo Dan was appointed executive director and chairman, Wang Liang was re-designated from chairman to vice chairman with his monthly salary cut from HK$300,000 to HK$200,000, and Zhang Lele resigned as a non-executive director.
On 20 November 2026, DONGJIANG ENV (00895.HK) said its Shaoxing unit was fined RMB920,000 and had RMB85,491.20 confiscated for overcharging on medical waste.
NIO-SW traded at HKD 20.960 on Nov 20, down 5.07%. Bin Li's NIO Users Trust, with Maples (Cayman) as trustee, holds 50 million shares via NIO Users Limited.
On 19 November 2026, AMStars closed a RMB 100 million-plus Series A from Guizhou S&T VC and other investors to build a new superalloy plant in Guiyang.
On 19 November 2026, JENSCARE-B (09877.HK) said the CSRC issued a filing notice for converting 74,227,021 domestic and unlisted foreign shares into H shares.
On 19 November 2026, GRANDPHARMA (00512.HK) said NMPA cleared a Phase I trial of GPN01564, its in-house RSV F protein inhibitor given by nebulization.
On 19 November 2026, FIRST CAP GP (01269.HK) said the High Court adjourned the scheme hearing to a date to be fixed; the debt restructuring remains uncertain.
On 19 November 2026, FS.COM (03355.HK) said the trustee bought 145,000 H shares at an average of HK$29.2014, lifting its trust holding to 1,370,700 shares.
On 19 November 2026, HUTCHMED (00013.HK) won China approval for two SYVIK NDAs in ITP and warm antibody AIHA, the first novel Syk inhibitor in the country.
On 19 November 2026, SC HOLDINGS (00413.HK) agreed to sell a first-floor unit in Des Voeux Road Central for HK$ 38,800,000, expecting a HK$ 6,000,000 gain.
On November 19, Hong Kong stocks opened lower, the Hang Seng Index down 1.95% on turnover of 229.5 billion HKD and southbound net buying of 3.959 billion HKD.















